In a forward genetic screen to identify genes required to tolerate aberrant MYC activation, Hsu et al identified that the core spliceosome is a novel dependency in MYC‐overexpressing breast cancers that can be targeted therapeutically. The gene discussed is MYC; the disease is breast carcinoma.